Is Trevi Therapeutics, Inc. (TRVI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 6.3% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 6.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.9% / 33% | 97.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 6.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.9% / 33% | 97.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -30.2% | |
| Return on Assets (ROA) | -20.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$38M |
| Free Cash Flow | -$38M |
| Total Debt | $1M |
| Debt-to-Equity | 0.4 |
| Current Ratio | 19.7 |
| Total Assets | $111M |
Price & Trading
| Last Close | $11.80 |
| 50-Day MA | $11.15 |
| 200-Day MA | $9.78 |
| Avg Volume | 1.4M |
| Beta | 1.0 |
|
52-Week Range
$4.85
| |
About Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Trevi Therapeutics, Inc. (TRVI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Trevi Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Trevi Therapeutics, Inc.'s debt ratio?
Trevi Therapeutics, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.9%.
What are Trevi Therapeutics, Inc.'s key financial metrics?
Trevi Therapeutics, Inc. has a market capitalization of $1.5B. Return on equity stands at -30.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.